Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 65, Issue 1, 2003, Pages 63-75

  Rustamzadeh, Edward ^a   Li, Chunbin ^b   Doumbia, Sekou ^c   Hall, Walter A ^a   Vallera, Daniel A ^a,b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b Sect on Molec Cancer Therapeutics   (United States)

^c R and D Systems Inc   (United States)

Author keywords

Diphtheria toxin; Glioblastoma; Immunotoxin; Nude mice; Urokinase

Indexed keywords

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CARMUSTINE; CYTOTOXIC AGENT; DENILEUKIN DIFTITOX; DIPHTHERIA TOXIN; DIPHTHERIA TOXIN INTERLEUKIN 13; DIPHTHERIA TOXIN INTERLEUKIN 4; DIPHTHERIA TOXIN VASCULOTROPIN; HYBRID PROTEIN; IMMUNOTOXIN; UNCLASSIFIED DRUG; UROKINASE; UROKINASE RECEPTOR;

AMINO TERMINAL SEQUENCE; ANTINEOPLASTIC ACTIVITY; BRAIN SURGERY; CANCER CELL; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER RESISTANCE; CATALYSIS; CELL CULTURE; CELL LINE; COGNITIVE DEFECT; DIGESTIVE SYSTEM ULCER; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXPOSURE; DRUG MIXTURE; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DRUG TARGETING; DRUG UPTAKE; ENDOTHELIUM CELL; ENHANCER REGION; GENE OVEREXPRESSION; GLIOBLASTOMA; HUMAN; HYPOPHYSIS DISEASE; HYPOTHALAMUS DISEASE; IN VITRO STUDY; IN VIVO STUDY; LEUKOMALACIA; NECROSIS; NEPHROTOXICITY; NEUROPATHY; NEUTROPENIA; NONHUMAN; OTOTOXICITY; PROTEIN BINDING; REVIEW; SIDE EFFECT; TREATMENT FAILURE; TUMOR VASCULARIZATION;

ANIMALS; BRAIN NEOPLASMS; DIPHTHERIA TOXIN; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; MICE; MICE, NUDE; RECEPTORS, CELL SURFACE; RECOMBINANT FUSION PROTEINS; URINARY PLASMINOGEN ACTIVATOR;

EID: 0345307772     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1026238331739     Document Type: Review

References (143)

1. Salcman M: Epidemiology and factors affecting survival. In: Appuzo MLJ (ed) Malignant Cerebral Glioma. American Association of Neurological Surgeons, Park Ridge, Il 1980, pp 95-110
2. Frankel SA, German WJ: Glioblastoma multiforme (review of 219 cases with regard to natural history, pathology, diagnostic methods, and treatment). J Neurosurg 489-503, 1985
3. Walker AE, Robins M, Weinfeld FD: Epidemiology of brain tumors: The national survey of intracranial neoplasms. Neurology 35: 219-226, 1985
4. Mehaley MS, Mettlin C, Natarajan N, Laws ER, Peace BB: National survey patterns of care for brain-tumor patients. J Neurosurg 71: 826-836, 1989
5. Davies E, Clarke C, Hopkins A: Malignant cerebral glioma-I: Survival, disability, and morbidity after radiotherapy. Br Med J 313: 1507-1512, 1996
6. Rutigliano MJ, Lunsford LD, Kondziolka D et al.: The cost effectiveness of stereotactic radiosurgery versus surgical resection in the treatment of solitary metastatic brain tumors. Neurosurgery 37: 445-455, 1995
7. Kirby S, Macdonald D, Fisher B et al.: Pre-radiation chemotherapy for malignant glioma in adults. Can J Neurol Sci 23: 123-127, 1996
8. Kristensen CA, Kristjansen PE, Hansen HH: Systemic chemotherapy of brain metastases from small-cell lung cancer: A review. J Clin Oncol 10: 1498-1502, 1992
9. McAllister LD, Doolittle ND, Gustadisegni PE et al.: Cognitive outcomes and long-term follow-up after enhanced chemotherapy delivery for primary central nervous system lymphomas. Neurosurgery 46: 51-61, 2000
10. Oddens EA, Shapiro WR: Brain tumors. Cancer Chemo Biol Response Modif 12: 615-633, 1991
11. Packer RJ: Chemotherapy for medulloblastoma/primitive neuroectodermal tumors of the posterior fossa. Ann Neurol 28: 823-828, 1990
12. Tomlinson FH, Scheithauer BW, Meyer FB et al.: Medulloblastoma I. Clinical, diagnostic, and therapeutic overview. J Child Neurol 7: 142-155, 1992
13. Williams PC, Henner WD, Roman-Goldstein S, Dahlborg SA et al.: Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain barrier in the treatment of intracranial neoplasms. Neurosurgery 37: 17-28, 1995
14. Walker MD, Green SB, Byar DP et al.: Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 303: 1323-1329, 1980
15. Nazarro JM, Neuwalt EA: The role of surgery in the management of supratentorial intermediate and high-grade astrocytomas in adults. J Neurosurg 73: 331-344, 1990
16. Salcman M: The morbidity and mortality of brain tumors. A perspective on recent advances in therapy. Neurol Clin 3: 229-257, 1985
17. Shapiro WR: Treatment of neuroectodermal brain tumors. Ann Neurol 12: 231-237, 1982
18. Hall WA, Djalilian HR, Sperduto PW, Cho KW et al.: Stereotactic radiosurgery for recurrent malignant gliomas. J Clin Oncol 13: 1642-1648, 1995
19. Hall WA, Fodstad Ø: Immunotoxins and central nervous system neoplasias. J Neurosurg 76: 1-12, 1992
20. Gonzalez-Vitale J, Garcia-Bunnuel R: Meningeal carcinomatosis. Cancer 37: 2906-2911, 1976
21. Olson M, Chernik N, Posner J: Infiltration of the leptomeninges by systemic cancer. A clinical and pathologic study. Arch Neurol 30: 122-137, 1974
22. Muraszko K, Sung C, Walbridge S, Greenfield L et al.: Pharmacokinetics and toxicology of immunotoxins administered into the subarachnoid space in nonhuman primates and rodents. Cancer Res 53: 3752-3757, 1993
23. Bindal RK, Sawaya R, Leavens ME, Lee JJ: Surgical treatment of multiple brain metastases. J Neurosurg 79: 210-216, 1993
24. Nussbaum ES, Djalilian HR, Hall WA: Brain metastases: Histology, multiplicity, surgery, and survival. Cancer 78(8): 1781-1788, 1996
25. Patchell RA, Tibbs PA, Walsh JW et al.: A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 322: 494-500, 1990
26. Greene GM, Hitchon PW, Schelper RL, Yuh W, Dyste GN: Diagnostic yield in CT-guided stereotactic biopsy of gliomas. J Neurosurg 71: 494-497, 1989
27. Kelly PJ, Daumas-Duport C, Kispert DB, Kall BA et al.: Imaging-based stereotactic serial biopsies in untreated intracranial glial neoplasms. J Neurosurg 66: 865-874, 1987
28. Burger PC, Heinz ER, Shibata T, Kleihues P: Topographic anatomy and CT correlations in the untreated glioblastoma multiforme. J Neurosurg 68: 698-704, 1988
29. 11C] methionine. J Comput Assist Tomogr 7: 1062-1066, 1983
30. Earnest F, Kelly PJ, Scheithauer BW, Kall BA et al.: Cerebral astrocytomas: Histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 166: 823-827, 1988
31. Kroll RA, Neuwelt EA: Outwitting the blood-brain barrier for therapeutic purposes: Osmotic opening and other means. Neurosurgery 42(5): 1083-1099, 1998
32. Skipper H: Historic milestones in cancer biology: A few that are important to cancer treatment (revisited). Semin Oncol 6: 506-514, 1979
33. Morrow C, Cowan K: Drug resistance and cancer. Adv Exp Med Biol 330: 287-305, 1993
34. Frankel AE, Kreitman RJ, Sausville EA: Targeted toxins. Clin Cancer Res 6: 326-333, 2000
35. Shockley TR, Lin K, Sung C, Nagy JA, Tompkins RG, Dedrick RL, Dvorak HF, Yarmush ML: A quantitative analysis of tumor-specific monoclonal antibody uptake by human melanoma xenografts: Effects of antibody immunological properties and tumor antigen expression levels. Cancer Res 52: 357-366, 1992
36. Sung C, Shockley TR, Morrison PF, Dvorak HF, Yarmush ML, Dedrick RL: Predicted and observed effects of antibody affinity and antigen density on monoclonal antibody uptake in solid tumors. Cancer Res 52: 377-384, 1992
37. Baxter LT, Yuan F, Jain RK: Pharmacokinetic analysis of the perivascular distribution of bifunctional antibodies and haptens: Comparison with experimental data. Cancer Res 52: 5838-5844, 1992
38. Jain RK: Delivery of novel therapeutic agents in tumors: Physiological barriers and strategies. J Natl Cancer Inst 81: 1989
39. Oldfield EH, Youle RJ: Immunotoxins for brain tumor therapy. Curr Top Microbiol Immunol 234: 97-114, 1998
40. Ehlrich P: The relationship between chemical constitution, distribution, and pharmacological action. In: Himmelweit F, Marquardt M, Dale H (eds) The Collected Papers of Paul Ehrlich, vol 1, Pergamon Press, Elmsford, NY, 1956, pp 596-618
41. Jansen FK, Blythman HE, Carriere D et al.: Immunotoxins: Hybrid molecules combining high specificity and potent cytotoxicity. Immunol Rev 62: 185-216, 1982
42. Vitetta E, Fulton R, May R et al.: Redesigning major positions to create antitumor reagents. Science 238: 1098-1104, 1987
43. Fostad Ø, Pihl A: Synergistic effect of ricin in combination with daunorubicin, cis-dichlorodiammineplatinum (II) and vincristine in systemic L1210 Leukemia. Cancer Res 42: 2152-2158, 1982
44. Remsen LG, Trail PA, Hellsotröm I, Hellsotröm KE, Neuwelt EA: Enhanced delivery improves the efficacy of a tumor-specific doxorubicin immunoconjugate in a human brain tumor xenograft model. Neurosurgery 46: 704-709, 2000.
45. Sjogren HO, Isaksson M, Willner D et al.: Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res 57: 4530-4536, 1997
46. Trail PA, Willner D, Lasch SJ et al.: Cure of xenografted human carcinomas by BR96-doxorubicin immunoconjugates. Science 261: 212-215, 1993
47. Remsen LG, Marquez C, Garcia R et al.: Efficacy after sequencing of brain radiotherapy enhanced antibody targeted chemotherapy delivery in a rodent human lung cancer brain xenograft model. Int J Radiat Oncol Biol Phys 51: 1045-1049, 2001
48. Akabani G, Cokgor I, Coleman RE, Trotter DG et al.: Dosimetry and dose-response relationships in newly diagnosed patients with malignant gliomas treated with iodine-131-labeled anti-tenascin monoclonal antibody 81C6 therapy. Int J Radiat Oncol Biol Phys 46(4): 947-958, 2000
49. Riva P, Franceschi G, Arista A et al.: Local application of radiolabeled monoclonal antibodies in the treatment of high grade malignant gliomas: A six-year clinical experience. Cancer 80(Suppl. 12): 2733-2742, 1997
50. 131I-labelled MAbs for the treatment of central nervous system malignancies. Br J Cancer 77: 2324-2330, 1998
51. Pizer BL, Papanastassiou V, Hancock J et al.: A pilot study of monoclonal targeted radiotherapy in the treatment of central nervous system leukemia in children. Br J Haematol 77: 466-472, 1991
52. 90Yttrium labelled monoclonal antibody MUC 2-63. In: Epenetos A (ed) Monoclonal Antibodies: Applications in Clinical Oncology. Chapman and Hall Medica, London, UK, 1992, pp 17-25
53. Papanastassiou V, Pizer BL, Coakam HB et al.: Treatment of recurrent and cystic malignant glioma by a single intracavitary injection of I-131 monoclonal antibody: Feasibility, pharmacokinetics, and dosimetry. Br J Cancer 67: 144-151, 1993
54. Youle RJ: Immunotoxins for central nervous system malignancy. Cancer Biol 7: 65-70, 1996
55. Siegall CB: Targeted toxins as anticancer agents. Cancer 74: 1006-1012, 1994
56. Faillot T, Magdelenat H, Mady E et al.: A phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery 39: 478-483, 1996
57. Manome Y, Watanabe M, Ohno T: The effect of immunotoxin against human glioma cells. Neurochir 32: 146-149, 1989
58. Zalutsky MR, Archer GE, Garg PK et al.: Chimeric anti-tenascin antibody 81C6: Increased tumor localization compared with its murine parent. Nucl Med Biol 23: 449-458, 1996
59. Hall WA: Immunotoxin therapy. Neurosurg Clin N Amer 7: 537-546, 1996
60. Engebraaten O, Hjortland GO, Juell S et al.: Intratumoral immunotoxin treatment of human malignant brain tumors in immunodeficient animals. Int J Cancer 97: 846-852, 2002
61. Frainkel AE, Tagge EP, Willingham MC: Clinical trials of targeted toxins. Cancer Biol 6: 307-317, 1995
62. Martell LA, Agrawal A, Ross DA, Murasko KM: Efficacy of transferin receptor-targeted immunotoxins in brain tumor cell lines and pediatric brain tumors. Cancer Res 53: 1348-1353, 1993
63. Zovickian J, Johnson VG, Youle RJ: Potent and specific killing of human malignant brain tumor cells by an anti-transferin receptor antibody-ricin immunotoxin. J Neurosurg 66: 850-861, 1987
64. Mujoo K, Cheung L, Murray JL: Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin. Cancer Immunol Immunother 40: 339-345, 1995
65. Baxter LT, Zhu H, Mackensen DG, Jain RK: Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice. Cancer Res 54: 1517-1528, 1994
66. Yokota T, Milenic DE, Whhitlow M, Schlom J: Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. Cancer Res 52: 3402-3408, 1992
67. Joshi BH, Leland P, Asher A et al.: In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures. Cancer Res 61: 8058-8061, 2001
68. Rand RW, Kreitman RJ, Patronas N et al.: Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6: 2157-2165, 2000
69. Yazdi PT, Murphy RM: Quantitative analysis of protein synthesis inhibition by transferrin-toxin conjugates. Cancer Res 54: 6387-6394, 1994
70. Laske DW, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3: 1362-1368, 1997
71. Kawakami K, Kawakami M, Puri RK: Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy. Crit Rev Immunol 21: 229-310, 2001
72. Debinski W, Obiri NI, Powers SK et al.: Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin Cancer Res 1: 1253-1258, 1995
73. Puri RK, Hoon DS, Leland P et al.: Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytomas. Cancer Res 56: 5631-5637, 1996
74. Pastan I, Fitzgerald D: Recombinant toxins for cancer treatment. Science 254: 1173-1177, 1992
75. Johnson VG, Wilson D, Greenfield L et al.: The role of the diphtheria toxin receptor in cytosol translocation. J Biol Chem 263: 1295-1300, 1988
76. Hall WA: Targeted toxin therapy. In: Kornblith PL, Walker MD (eds) Advances in Neuro-Oncology II. Futura Armonk, NY, 1997, 505-516
77. Fitzgerald DJ, Willingham MC, Cardarelli CO et al.: A monoclonal antibody-Pseudomonas toxin conjugate that specifically kills multidrug-resistant cells. Proc Natl Acad Sci USA 84: 4288-4292, 1987
78. Hertler AA, Frankel AE: Immunotoxins: A clinical review of their use in the treatment of malignancies. J Clin Oncol 7: 1933-1942, 1989
79. McNally NJ: Enhancement of chemotherapy agents. Int J Radiat Oncol Biol Phys 8: 593-598, 1982
80. Jain RK, Baxter LT; Mechanism of heterogeneous distribution of monoclonal antibodies and other macromolecules in tumors: Significance of elevated interstitial pressure. Cancer Res 48: 7022-7032, 1988
81. Baxter LT, Jain RK: Transport of fluid and macromolecules in tumors I. Role of interstitial pressure and convection. Microvasc Res 37: 77-102, 1989
82. Jain RK: Transport of molecules in the tumor interstitium: A review. Cancer Res 47: 3039-3051, 1987
83. Wiig H, Tveit E, Hultborn R et al.: Interstitial fluid pressure in DMBA-induced rat mammary tumors. Scand J Clin Lab Invest 42: 159-164, 1982
84. Misiewicz M: Microvascular and interstitial pressures in normal and neoplastic iissues. M.S. Thesis Pittsburgh, Carnegie Mellon University, 1986
85. Sylven B, Bois I: Protein content and enzymatic assays of interstitial fluid from some normal tissues and transplanted mouse tumors. Cancer Res 20: 831-835, 1960
86. Weistein JN, Eger RR, Covell DG et al.: The pharmacology of monoclonal antibodies. Ann NY Acad Sci 507: 199-210, 1987
87. Dedrick RL, Flessner MF: Pharmacokinetic considerations of monoclonal antibodies. Prog Clin Biol Res 288: 429-438, 1989
88. Capone PM, Papsidero LD, Chu TM: Relationship between antigen density and immunotherapeutic response elicited by monoclonal antibodies against solid tumors. J Natl Cancer Inst 72: 673-677, 1984
89. Wen DY, Hall WA, Conrad J, Godal A, Florenes VA, Fodstad O: In vitro and in vivo variation in transferring receptor expression on a human medulloblastoma cell line. Neurosurgery 36: 1158-1163, 1995
90. Peter RU, Beetz A, Ried C et al.: Increased expression of the epidermal growth factor receptor in human epidermal keratinocytes after exposure to ionizing radiation. Radiat Res 136: 65-70, 1993
91. Schmidt-Ulrich RK, Valerie K, Chan W et al.: Expression of oestrogen receptor and transforming growth factor in MCF-7 cells after exposure to fractionated irradiation. Int J Radiat Biol 61: 405-415, 1992
92. Schmidt-Ulrich RK, Valerie K, Chan W et al.: Altered expression of epidermal growth factor receptor and estrogen receptor in MCF-7 cells after single and repeated radiation exposures. Int J Radiat Oncol Biol Phys 29: 813-819, 1994
93. Schmidt-Ulrich RK, Valerie K, Chan W et al.: Radiation-induced autophosphorylation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat Res 145: 81-85, 1996
94. 390-anti-CD3sFv, a single chain FV fusion immunotoxin specifically targeting the CD3 epsilon moiety of the T cell receptor. Blood 88: 2342, 1996
95. Chan C-H, Blazar BR, Eide CR, Kreitman RJ, Vallera DA: A murine cytokine fusion toxin specifically targeting the murine GM-CSF receptor on normal committed bone marrow progenitor cells and GM-CSF dependent tumor cells. Blood 86: 2732, 1995
96. 390-mIL-3, with bone marrow progenitor cells 1,2. Blood 88: 1445, 1996
97. Colombatti M, Greenfield L, Youle RJ: Cloned fragment of diphtheria toxin linked to T-cell-specific antibody identifies regions of B chain active in cell entry. J Biol Chem 261: 3030-3035, 1986
98. Williams DP, Snider CE, Strom TB, Murphy JR: J Biol Chem 265: 11885-11889, 1990
99. Nichols P, Youle RJ: Structure of diphtheria toxin as a guide to rational design. In: Frankel AE (ed) Genetically Engineered Toxins. Marcel Dekker, New York, 1992, p 339
100. Collier JR: Structure-activity relationships in diphtheria toxin and Pseudomonas aeruginosa exotoxin A. In: Frankel AE (ed) Immunotoxins. Kluwer Academic Publishers, Norwell, MA, 1988, p 25
101. Vallera DA, Kuroki DW, Panoskaltsis-Mortari A, Buchbaum DJ, Blazar BR: Molecular modification of recombinant immunotoxin inducing terminal cysteine bridging reduces toxicity and enhances the anti-GVHD effect in a lethal murine model. Blood 96: 1157, 2000
102. Woolley DE: Collagenolytic mechanisms in tumor cell invasion. Cancer Metast Rev 3: 361-372, 1984
103. Reich R, Thompson EW, Iwamoto YY et al.: Effects of inhibitors of plasminogen activator, serine proteases, and collagenase IV on the invasion of basement membranes by metastatic cells. Cancer Res 48: 3307-3312, 1988
104. Ossowski L, Clunie G, Masucci MT et al.: In vivo paracrine interaction between urokinase and its receptor: Effect on tumor cell invasion. J Cell Biol 115: 1107-1112, 1991
105. Abe T, Mori T, Kohno K et al.: Expression of 72-Dka type IV collagenase and invasion activity of human glioma cells. Clin Exp Metastasis 12: 296-304, 1994
106. Declerck YA, Perez N, Shimada HH et al.: Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. Cancer Res 52: 701-708, 1992
107. Christensen L, Simonsen ACW, Heegaard CW et al.: Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and α-2-macroglobulin receptor in human breast carcinomas. Int J Cancer 66: 441-452, 1996
108. Fabrini MS, Carpani D, Bello-Rivero I et al.: The amino-terminal fragment of human urokinase directs a recombinant chimeric toxin to target cells: Internalization is toxin mediated. FASEB J 11: 1169-1176, 1997
109. Grøndahl-Hansen J, Peters HA, Van Putten WLJ et al.: Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1: 1079-1087, 1995
110. Blasi F: uPA, uPAR, PAI-1: Key intersection of proteolytic, adhesive and chemotactic highways? Trends Immunol Today 18: 415-417, 1997
111. Roldan AL, Cubellis MV, Masucci MT et al.: Cloning and expression of the receptor for human urokinase plasminogen activator, a central molecule in cell surface, plasmin dependent proteolysis. EMBO J 9: 467-474, 1990
112. Behrendt N, Rønne E, Ploug M et al.: The human receptor for urokinase plasminogen activator. J Biol Chem 265: 6453-6460, 1990
113. Høyer-Hansen G, Rønne E, Behrendt N et al.: Urokinase plasminogen activator cleaves its cell surface receptor releasing the ligand-binding domain. J Biol Chem 267: 18224-18229, 1992
114. Waltz DA, Chapman HA: Reversible cellular adhesion to vitronectin linked to urokinase receptor occupancy. J Biol Chem 269: 14746-14750, 1994
115. Wei Y, Waltz DA, Rao N et al.: Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269L 32380-32388, 1994
116. Resnati M, Guttinger M, Valcamonica S et al.: Proteolytic cleavage of the urokinase receptor substitutes for the agonist-induced chemotactic effect. EMBO J 15: 1572-1582, 1996
117. De Vries TJ, Mooy CM, Van Balken MR et al.: Components of the plasminogen activation system in uveal melanoma - A clinico-pathological study. J Pathol 175: 59-67, 1995
118. Versgaet HW, Sier CF, Ganesh S et al.: Prognostic value of plasminogen activators and their inhibitors in colorectal cancer. Eur J Cancer 31A: 1105-1109, 1995
119. Crowley CW, Cohen RL, Lucas BK et al.: Prevention of metastasis by inhibition of the urokinase receptor. Proc Natl Acad Sci USA 90: 5021-5025, 1993
120. Mori T, Abe T, Wakabayashi Y et al.: Up-regulation of urokinase-type plasminogen activator and its receptor correlates with enhanced invasion activity of human glioma cells mediated by transforming growth factor-alpha or basic fibroblast growth factor. J Neuro-Oncol 46: 115-123, 2000
121. Vallera DA, Li C, Jin N et al.: Targeting urokinase-type plasminogen activator receptor on human glioblastoma tumors with diphtheria toxin fusion protein DTAT. J Natl Cancer Inst 94: 597-606, 2002
122. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82: 4-6, 1990
123. Olson TA, Mohanraj D, Roy S, Ramakrishnan S: Targeting the tumor vasculature: Inhibition of tumor growth by a vascular endothelial growth factor-toxin conjugate. Int J Cancer 73: 865-870, 1997
124. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE: Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 275: 547-550, 1997
125. Beitz JG, Davol-Lewis P, Clark JW, Kato J, Medina M, Frackelton AR, Lappi DA, Baird A, Calabresi P: Antitumor activity of basic FGF-saporin mitotoxin in vitro and in vivo. Cancer Res 52: 227-230, 1992
126. Burrows FJ, Thorpe PE: Eradication of large solid tumors in mice with an immunotoxin directed against the tumor vasculature. Proc Natl Acad Sci 90: 8996-9000, 1993
127. Gawlak SL, Pastan I, Siegall CB. Basic fibroblast growth factor. Pseudomonas exotoxin chimeric proteins: Comparison with acidic fibroblast growth factor - Pseudomonas exotoxin. Bioconjug Chem 4: 483-489, 1993
128. Ramakrishnan S, Olson TA, Bauch VL, Mohanraj D. Vascular endothelial growth factor-toxin conjugate specifically inhibits KDR/flk-1-positive endothelial cell proliferation in vitro and angiogenesis in vivo. Cancer Res 56: 1324-1330, 1996
129. Solberg H, Ploug M, Høyer-Hansen G et al.: The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J Histochem Cytochem 49: 237-246, 2001
130. Fulcher S, Lui GM, Houston LL et al.: Use of immunotoxin to inhibit proliferating human corneal endothelium. Invest Opthalmol Vis Sci 29: 755-759, 1988
131. Debinski W, Gibo DM, Hulet SW, Connor JR, Gillespie GY: Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clin Cancer Res 5: 985-990, 1999
132. Debinski W, Obiri NI, Powers SK et al.: Human glioma cells overexpress receptors for interleukin 13 and are extremely sensitive to a novel chimeric protein composed of interleukin 13 and Pseudomonas exotoxin. Clin Cancer Res 1: 1253-1258, 1995
133. Zurawski G, De Vries JE: Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 15: 1994
134. Brown KD, Zurawski SM, Mosmann TR, Zurawski G: A family of small inducible proteins secreted by leukocytes are members of a new super-family that includes leukocyte and fibroblast-derived inflammatory agents, growth factors, and indicators of various activation processes. J Immunol 142: 679, 1989
135. Minty A, Chalon P, Derocq J-M, Dumont X, Guillemot J-C, Kaghad M, Labit C, Leplatois P, Liauzum P, Miloux B, Minty C, Casekkas P, Loison G, Lupker J, Shire D, Ferrara P, Caput D: Interleukin-13 is a new human lymphokine regulating inflammatory and immune responses. Nature 362: 248, 1993
136. Obiri NI, Leland P, Murata T, Debinski W, Puri RK: The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J Immunol 158: 756-764, 1997
137. Debinski W: An immune regulatory cytokine receptor and glioblastoma multiforme an unexpected link. Crit Rev Oncog 9: 255-268, 1998
138. Li C, Hall WA, Jin N et al.: Targeting glioblastoma multiforme with an IL-13/diphtheria toxin fusion protein in vitro and in vivo in nude mice. Protein Eng 15: 419-427, 2002
139. Rand RW, Kreitman RJ, Patronas N, Varricchio F, Pastan I, Puri RK: Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma. Clin Cancer Res 6: 2157-2165, 2000
140. Debinski W, Gibo DM, Hulet SW et al.: Receptor for interleukin 13 is a marker and therapeutic target for human high grade gliomas. Clin Cancer Res 5: 985-990, 1999
141. Hussain SR, Joshi BH, Puri RK et al.: Interleukin-13 receptor as a unique target for anti-glioblastoma therapy. Int J Cancer 92: 168-175, 2001
142. Debinski W: Local treatment of brain tumors with targeted chimera cytotoxic proteins. Cancer Invest 20(5-6): 801-809, 2002 (Review)
143. Laske DW, Youle RJ, Oldfield EH: Tumor regression with regional distribution of the targeted toxin TF-CRM107 in patients with malignant brain tumors. Nat Med 3: 1362-1368, 1997